Aytu Biopharma (AYTU) Profit After Tax (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Profit After Tax data on file, last reported at -$5.6 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 240.66% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$34.7 million, a 798.67% decrease from a year earlier, with the FY2025 full-year figure at -$14.2 million, down 13.27% from the prior year.
• Profit After Tax for Q1 2026 stood at -$5.6 million, up from -$10.6 million in the prior quarter.
• Over the last five years, Profit After Tax for AYTU reached as high as $4.0 million in Q1 2025 and fell as low as -$53.3 million in Q1 2022.
• Historically, Profit After Tax has averaged -$7.5 million across 5 years, with a median of -$2.5 million in 2023.
• Across the five-year window, Profit After Tax soared 458.18% in 2024 and plunged 1480.67% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$6.7 million in 2022, then jumped by 96.71% to -$220000.0 in 2023, then surged by 458.18% to $788000.0 in 2024, then plunged by 1443.15% to -$10.6 million in 2025, then soared by 46.92% to -$5.6 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$5.6 million in Q1 2026, -$10.6 million in Q4 2025, and $2.0 million in Q3 2025.